Sutekast

Sutekast Capsule

Sutekast Salt is an indolinone simulator and tyrosine inhibitor with latent antineoplastic activity. Sunitinib Malate blocks the activity of vascular endothelial kinase 2 (VEGFR2) receptors, platelets – producing growth factor b (PDGFRb) and c-kit receptors, which limit angiogenesis and cell proliferation. These mediators also counteract the phosphorylation of tyrosine kinase 3 associated with Fms (FLT3), another tyrosine kinase receptor articulated by some leukemia cells.

This salt was originally approved in the United States in 2006. Since, the expiration of the US patent, it has been manufactured and used in India.

How does Sutekast (Sunitinib Malate) work?

Sutekast (Sunitinib Malate) prevents the movement of multiple receptor tyrosine kinases (RTKs). These include all platelet-derived growth function receptors (PDGF-Rs) and vascular endothelial growth function receptors (VEGFR), which play important roles in tumor cell proliferation and angiogenesis. Therefore, direct reserve of this target reduces tumor vascularization and activates apoptosis of cancer cells, thereby causing tumor shrinkage.

This salt also prevents CD117 (c-KIT), a tyrosine kinase receptor which (if not properly activated by alteration) supplies energy to the main stream of intestinal stromal cell tumor. It is recommended as second-line therapy for patients whose tumors have increased c-KIT mutations, which make imatinib infection more difficult, or who cannot tolerate the drug.

In addition, sunitinib confuses other compromised receptors:

RET

CD135

CD114

Sutekast (Sunitinib Malate) targets multiple receptors that cause various side effects, such as classic arm and leg syndrome, stomatitis, and other dermatological toxicities.

Usage and Indications

It is a kinase inhibitor used to treat:

• Gastrointestinal stromal tumor (GIST) after disease that develops on imatinib mesylate or is affected by imatinib mesylate
• Progressive and well-differentiated neuroendocrine pancreatic tumor (pNET) in patients with inoperable metastatic or advanced disease.
• Advanced Renal Cell Carcinoma (RCC)

Dosage & Administration

Recommended dosage for adjuvant treatment of RCC

The scheduled dose of Sutekast (Sunitinib Malate) for adjuvant RCC treatment is 50 mg orally once daily with a one-month treatment schedule, followed by 15 days off for a six-week cycle. Sutekast can be consumed with or without food.

Recommended dosage for pNET

The recommended dose for pNET (a progressive and well-differentiated neuroendocrine pancreatic tumor) is 37.5 mg orally daily. Continuously without a scheduled off-treatment period. Patients can take it with or without food.

Dosage Forms & Strengths

12.5 mg capsule

Hard jelly capsule with orange cap and orange body, with the stamp “Sutekast” on the lid and “SUTEKAST 12.5 mg” on the body.

25 mg capsule

Hard jelly capsules with caramel caps and orange body, with the stamp “Sutekast” on the lid and SUTEKAST-25 – Sutekast capsules 25 mg on the body.

50 mg capsule

Hard jelly capsules with caramel caps and orange body, with the brand “Sutekast” on the lid and SUTEKAST-50 – Sutekast 50 mg capsules on the body.

Side Effects

Sunitinib Malate Capsule is measured in a controllable manner and the incidence of side effects is extremely low.

The most common side effects of sunitinib (Sunitinib Malate) therapy are diarrhea, nausea, fatigue, yellowing of the skin, high blood pressure, stomatitis, and skin reactions on the hands and feet. During Phase III placebo-controlled GIST studies, side effects often included asthenia, change in taste, constipation, skin discoloration, diarrhea, stomatitis, and anorexia.

Dose reductions were required in more than 50% of patients tested at the RCC to overcome the important toxicity of this compound.

Extreme frequency (Grade 3 or 4) occurs in ≤ 10% of patients and includes diarrhea, high blood pressure, fatigue and chemotherapy-induced acrylic erythema. Laboratory abnormalities associated with Sutekast’s therapy include amylase, lipase, platelets, lymphocytes, and neutrophils. Reversible erythrocytosis and hypothyroidism are also associated with it.

It can control most unpleasant events through maintenance therapy, dose discontinuation, or dose reduction.

Warnings & Precautions

Hepatotoxicity

Hepatotoxicity with liver failure has been observed. Before starting treatment, monitor liver function tests for each treatment cycle and according to clinical indications. It should be disturbed for grade 3 or grade 4 medicine associated hepatic opposing events and discontinued if solutions are not available. In this case, do not restart Sutekast (Sunitinib Malate) if the patient has extreme changes in liver function tests or has other signs and symptoms of liver failure.

Pregnancy

Pregnant women should be informed about the potential risks to the fetus and avoid pregnancy.

Left ventricular dysfunction

Cardiac toxicity and left ventricular output were below normal lower limits. Heart failure and death has occurred – monitor the patient for signs and symptoms of heart failure.

Hypertension

High blood pressure can develop, which requires blood pressure monitoring and medication.

Hemorrhagic Events

Hemorrhagic events have occurred, including discharge associated with the tumor. Perform sequential complete blood checks and actual assessments.

Thyroid dysfunction

Thyroid dysfunction may occur. Patients with signs and indications reminiscent of hypothyroidism or hyperthyroidism should undergo laboratory tests for thyroid capacity and should be treated according to standard clinical practice.

Wound healing

Sutekast’s temporary discontinuation is recommended in patients undergoing major surgery.

How to save Sutekast (Sunitinib Malate)?

It should be stored at room temperature between 20 ° C and 25 ° C. Keep it and all other medicines out of reach of children.

Materials used

Sutekast (Sunitinib Malate)

Inactive ingredients

Povidone (K-25) and magnesium stearate, Croscarmellose Sodium

Note: We are also exporting to countries: Malaysia, Indonesia, Philippines, Venezuela and Korea.